Elite in Rheumatoid Arthritis (RA)

Patrick C. Verschueren

Leuven, VLG, BE 
Elite in Rheumatoid Arthritis (RA)
Leuven, VLG, BE 
OverviewLocationsClinical Research

Overview

Patrick Verschueren practices in Leuven, Belgium. Mr. Verschueren is rated as an Elite expert by MediFind in the treatment of Rheumatoid Arthritis (RA). His top areas of expertise are Rheumatoid Arthritis (RA), Arthritis, Rheumatoid Lung Disease, and COVID-19.

His clinical research consists of co-authoring 159 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 118 articles and participated in 2 clinical trials in the study of Rheumatoid Arthritis (RA).

Gender
Male

Locations

Leuven, VLG, Belgium
Other Locations
Lueven, Belgium
Brussels, BRU, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase IIa Randomized, Double Blind, Placebo Controlled, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to Anti-Tnfα, or Intolerance to Anti-Tnfα
Phase IIa Randomized, Double Blind, Placebo Controlled, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to Anti-Tnfα, or Intolerance to Anti-Tnfα
Enrollment Status: Completed
Publish Date: February 15, 2023
Intervention Type: Drug
Study Drugs: ABX464, Methotrexate
Study Phase: Phase 2
A Follow-up Phase 2a Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 in Patients With Moderate to Severe Active Rheumatoid Arthritis
A Follow-up Phase 2a Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 in Patients With Moderate to Severe Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Drug: ABX464
Study Phase: Phase 2
View 1 Less Clinical Trial

159 Total Publications

Serum calprotectin and complement factor C3 are superior biomarkers of inflammation in early psoriatic arthritis as compared with C-reactive protein.
Serum calprotectin and complement factor C3 are superior biomarkers of inflammation in early psoriatic arthritis as compared with C-reactive protein.
Journal: RMD open
Published: June 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Verschueren's expertise for a condition
ConditionClose
    View All 21 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile